文献速递肝病消化道肿瘤与早癌

非酒精性脂肪性肝病中适度饮酒是好是坏?一篇批判性综述

Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review.
PubMed 文献 · Hepatology · 2017-04-28

本文批判性综述了非酒精性脂肪性肝病患者适度饮酒对心血管与肝脏健康的影响。共纳入7项观察性研究(心血管终点1项、肝脏终点6项),发现适度饮酒与NASH和纤维化减少呈正相关,但重度间歇性饮酒可能加速纤维化进展,适度饮酒可能增加晚期纤维化患者肝细胞癌风险;因方法学局限明显,尚不能对适度饮酒的获益作出强烈推荐。

要点

  • 适度饮酒与NASH和纤维化减少呈正相关,但证据来自观察性研究。
  • 重度间歇性饮酒可能加速纤维化进展,适度饮酒可能增加晚期纤维化患者肝细胞癌风险。
  • 现有研究存在混杂因素调整不充分、未测量终生饮酒量或饮酒模式等方法学局限。

核心结论

  • 尚不能对非酒精性脂肪性肝病患者适度饮酒的获益作出强烈推荐。
  • 仍需开展评估非酒精性脂肪性肝病患者适度或更少量饮酒后心血管与肝脏结局的高质量纵向研究。

研究设计与样本

  • 本文为批判性综述,共纳入7项符合标准的观察性研究,中心血管终点1项、肝脏终点6项。
  • 研究检索并评估了非酒精性脂肪性肝病患者适度饮酒对心血管与肝脏疾病影响的文献。

主要发现

  • 适度饮酒与NASH和纤维化减少呈正相关。
  • 重度间歇性饮酒可能加速纤维化进展。
  • 适度饮酒可能增加晚期纤维化患者肝细胞癌的风险。
  • 评估适度饮酒与心血管结局关联的研究不足。

关键数值与推荐

  • 纳入标准:观察性研究,共7项(心血管终点1项、肝脏终点6项)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 存在显著的方法学局限,包括对混杂因素调整不充分。
  • 未测量终生饮酒量或饮酒模式。
  • 评估适度饮酒与心血管结局关联的研究不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Moderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects on cardiovascular and liver health are unclear. Moderate alcohol use is associated with improved insulin sensitivity and decreased cardiovascular mortality in the general population, but whether similar benefits would be observed in persons with NAFLD remains largely unstudied. There is significant overlap in the pathogenesis of alcoholic liver disease (ALD) and NAFLD, although studies of ALD have focused on pathological alcohol intake and few mechanistic studies of moderate alcohol use in NAFLD exist. We undertook a critical review of the effect of moderate alcohol use on cardiovascular and liver disease in patients with NAFLD. A total of seven observational studies met the criteria for inclusion (one for cardiovascular endpoints and six for liver endpoints). Insufficient studies have assessed the association of moderate alcohol use with cardiovascular outcomes. There was a positive association between moderate alcohol use and decreased NASH and fibrosis; however, heavy episodic drinking may accelerate fibrosis progression and moderate alcohol use may increase the risk of hepatocellular carcinoma in patients with advanced fibrosis. Significant methodological limitations were present, including incomplete adjustment for confounding factors and failure to measure lifetime use or the pattern of alcohol intake. Thus, a strong recommendation of benefit of moderate alcohol use in NAFLD cannot be made. There remains a need for additional high-quality longitudinal studies that evaluate both cardiovascular and liver outcomes among NAFLD patients with moderate or lesser degrees of alcohol use. (Hepatology 2017;65:2090-2099).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ajmera VH, Terrault NA, Harrison SA, et al. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017. PMID: 28100008. doi:10.1002/hep.29055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。